Additional limitations include: (1) continuous glucose supply tumor vasculature, potentially overcome by combining anti-angiogenic agents [31,41], and (2) metabolic reprogramming via LOXL2-mediated glycolytic enzyme activation, suggesting therapeutic potential in dual GOX/LOXL2 inhibition [75]. Here, LOXL2 is linked to neoplasm.